Precision and predictive medicine in urothelial cancer: Are we making progress?

noticia |

Bellmunt J., Orsola A., Sonpavde G.


European Urology 2015 68:4 (547-549)

Take Home Message Therapy for urothelial carcinoma appears poised for a breakthrough on the basis of information regarding molecular subtypes and promising activity of PD-1/PD-L1 inhibitors. Precision medicine may be possible using rational marker-driven trial designs with enriched information from tumor genotyping and extreme responders.


1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)